CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

GM-2040

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionOct 19, 2025
Entity authorityQ133270298 ↗
Source-derived summary

GM-2040 is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist which was developed by Gilgamesh Pharmaceuticals. It is a partial agonist of the serotonin 5-HT2A receptor, with a Ki of 3.4 nM, an EC50Tooltip half-maximal effective concentration of 43.8 nM, and an EmaxTooltip maximal efficacy of 71.1%. Relative to the serotonergic psychedelic DOPR, the drug only weakly produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence may not produce hallucinogenic effects in humans. On the other hand, GM-2040 shows robust and persistent antidepressant-like effects in rodents.

Editorial summary

Begin with the source’s own compact description: “GM-2040” is pharmaceutical compound. The dossier treats that line as a proposition to test through GM-2040, pharmaceutical and compound, not as a finished interpretation.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current lead gives the account dated anchors—2040—that can be checked directly. The selected authority fields contribute no independent date. For this dossier, GM-2040, pharmaceutical and compound is the immediate research focus.
Editorial analysis

Why this record matters

The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.

Evidence profile

Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Oct 19, 2025. The linked authority identifier is Q133270298. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2040.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “GM-2040”, its source revision and the description used here.
  2. Expand the search: follow GM-2040 primary sources, GM-2040 archive and GM-2040 research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “GM-2040”?
  2. Which institution is responsible for the underlying evidence?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “GM-2040” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.